Energy‐Coupling Factor Transporters as Novel Antimicrobial Targets
dc.contributor.author | Bousis, Spyridon | |
dc.contributor.author | Diamanti, Eleonora | |
dc.contributor.author | Slotboom, Dirk J. | |
dc.contributor.author | Hirsch, Anna K. H. | |
dc.date.accessioned | 2019-02-20T10:42:06Z | |
dc.date.available | 2019-02-20T10:42:06Z | |
dc.date.issued | 2019-02 | |
dc.identifier.doi | 10.1002/adtp.201800066 | |
dc.identifier.uri | https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.201800066 | |
dc.identifier.uri | http://hdl.handle.net/10033/621700 | |
dc.description.abstract | In an attempt to find new antibiotics, novel ways of interfering with important biological functions should be explored, especially with those which are necessary or even irreplaceable for bacterial survival, growth, and virulence. The purpose of this review is to highlight B‐type vitamin transporters from the energy‐coupling factor (ECF) family, which are not present in humans, as potential antimicrobial targets. In addition, a druggability analysis of an ECF transporter for folic acid and sequence‐conservation studies in seven prominent pathogens revealed new druggable pockets. Evaluation of the presence of de novo biosynthetic routes for the vitamins in question in the seven pathogens confirmed that this target class holds promise for the discovery of antimicrobial drugs with a new mechanism of action, possibly on a broad‐spectrum level. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Wiley-Blackwell | en_US |
dc.relation | info:eu-repo/grantAgreement/EC/H2020/757913 | en_US |
dc.rights | openAccess | en_US |
dc.rights | Attribution-NonCommercial-ShareAlike 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
dc.subject | antimicrobials | en_US |
dc.subject | B-type vitamins | en_US |
dc.subject | energy coupling factor transporters | en_US |
dc.subject | S-components | en_US |
dc.subject | uptake | en_US |
dc.title | Energy‐Coupling Factor Transporters as Novel Antimicrobial Targets | en_US |
dc.type | Article | en_US |
dc.identifier.eissn | 2366-3987 | |
dc.contributor.department | HIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany. | en_US |
dc.identifier.journal | Advanced Therapeutics | en_US |
refterms.dateFOA | 2019-02-20T10:42:06Z |